Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR 208.83
+3.28 (1.60%)
Apr 29, 2026, 3:29 PM IST
Jagsonpal Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2021 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2021 - 2017 |
| Operating Revenue | 2,872 | 2,687 | 2,087 | 2,367 | 2,176 | Upgrade
|
| Other Revenue | 119.95 | - | - | - | - | Upgrade
|
| Revenue | 2,992 | 2,687 | 2,087 | 2,367 | 2,176 | Upgrade
|
| Revenue Growth (YoY) | 11.35% | 28.76% | -11.83% | 8.79% | 15.77% | Upgrade
|
| Cost of Revenue | 1,044 | 969.61 | 805.48 | 926.98 | 896.91 | Upgrade
|
| Gross Profit | 1,948 | 1,718 | 1,282 | 1,440 | 1,279 | Upgrade
|
| Selling, General & Admin | 707.4 | 820.97 | 635.52 | 729.76 | 703.71 | Upgrade
|
| Other Operating Expenses | 540.36 | 317.83 | 272.55 | 269.53 | 319.67 | Upgrade
|
| Operating Expenses | 1,342 | 1,288 | 1,065 | 1,101 | 1,039 | Upgrade
|
| Operating Income | 606.25 | 429.4 | 216.07 | 338.85 | 239.87 | Upgrade
|
| Interest Expense | -10.28 | -8.58 | -7.77 | -2.78 | -2.61 | Upgrade
|
| Interest & Investment Income | - | 76.45 | 85.92 | 34.28 | 15.46 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 4.45 | 4.47 | 3.11 | 1.5 | Upgrade
|
| EBT Excluding Unusual Items | 595.97 | 501.72 | 298.69 | 373.46 | 254.22 | Upgrade
|
| Merger & Restructuring Charges | - | -34.97 | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | -0.3 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 5.92 | 11.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 3.59 | 0.85 | Upgrade
|
| Asset Writedown | - | -1.75 | - | -27.79 | - | Upgrade
|
| Other Unusual Items | -20.79 | 233.59 | - | -6.8 | - | Upgrade
|
| Pretax Income | 575.18 | 698.59 | 298.69 | 348.08 | 266.42 | Upgrade
|
| Income Tax Expense | 144.36 | 144.98 | 74.06 | 80.87 | 77.87 | Upgrade
|
| Net Income | 430.82 | 553.61 | 224.63 | 267.21 | 188.55 | Upgrade
|
| Net Income to Common | 430.82 | 553.61 | 224.63 | 267.21 | 188.55 | Upgrade
|
| Net Income Growth | -22.18% | 146.45% | -15.93% | 41.72% | 10.53% | Upgrade
|
| Shares Outstanding (Basic) | 67 | 67 | 66 | 65 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 67 | 66 | 65 | 65 | Upgrade
|
| Shares Change (YoY) | 1.40% | 1.56% | 1.23% | - | - | Upgrade
|
| EPS (Basic) | 6.40 | 8.26 | 3.40 | 4.08 | 2.88 | Upgrade
|
| EPS (Diluted) | 6.31 | 8.22 | 3.39 | 4.08 | 2.88 | Upgrade
|
| EPS Growth | -23.24% | 142.48% | -16.91% | 41.72% | 10.55% | Upgrade
|
| Free Cash Flow | 466.64 | 549.52 | 349.18 | 463.37 | 58.65 | Upgrade
|
| Free Cash Flow Per Share | 6.83 | 8.16 | 5.27 | 7.08 | 0.90 | Upgrade
|
| Dividend Per Share | - | 2.500 | 2.000 | 2.000 | 1.600 | Upgrade
|
| Dividend Growth | - | 25.00% | - | 25.00% | 300.00% | Upgrade
|
| Gross Margin | 65.12% | 63.92% | 61.41% | 60.84% | 58.78% | Upgrade
|
| Operating Margin | 20.26% | 15.98% | 10.35% | 14.31% | 11.02% | Upgrade
|
| Profit Margin | 14.40% | 20.60% | 10.76% | 11.29% | 8.67% | Upgrade
|
| Free Cash Flow Margin | 15.60% | 20.45% | 16.73% | 19.57% | 2.70% | Upgrade
|
| EBITDA | 700.69 | 496.31 | 221.13 | 347.11 | 255.13 | Upgrade
|
| EBITDA Margin | 23.42% | 18.47% | 10.60% | 14.66% | 11.73% | Upgrade
|
| D&A For EBITDA | 94.44 | 66.91 | 5.06 | 8.26 | 15.26 | Upgrade
|
| EBIT | 606.25 | 429.4 | 216.07 | 338.85 | 239.87 | Upgrade
|
| EBIT Margin | 20.26% | 15.98% | 10.35% | 14.31% | 11.02% | Upgrade
|
| Effective Tax Rate | 25.10% | 20.75% | 24.80% | 23.23% | 29.23% | Upgrade
|
| Revenue as Reported | 2,992 | 2,769 | 2,180 | 2,424 | 2,210 | Upgrade
|
| Advertising Expenses | - | 175.42 | 138.58 | 147.3 | 102.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.